Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(20%)
Results Posted
167%(5 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
5
100%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
75.0%
Most Advanced
Phase 1

Trials by Phase

Phase 15 (100.0%)

Trials by Status

terminated120%
active_not_recruiting120%
completed360%

Recent Activity

1 active trials
Showing 5 of 5
active_not_recruitingphase_1

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04126200
completedphase_1

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

NCT02723955
completedphase_1

Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors

NCT03447314
terminatedphase_1

Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

NCT06160609
completedphase_1

GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)

NCT02528357

Clinical Trials (5)

Showing 5 of 5 trials
NCT04126200Phase 1

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Active Not Recruiting
NCT02723955Phase 1

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Completed
NCT03447314Phase 1

Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors

Completed
NCT06160609Phase 1

Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

Terminated
NCT02528357Phase 1

GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5